COVID-19

Whether it be delivery options, remote pharmacy, increasing roles for pharmacists and technicians, or fluctuating patient volume, the impact of COVID-19 can be felt in community pharmacies across the United States.

Critically ill patients admitted to the intensive care unit (ICU) with coronavirus disease 2019 (COVID-19) are 10 times more likely to develop cardiac arrhythmias.

In addition to allopathic or prescription medications to manage depression stemming from this pandemic, there are integrative medicines, as well as health and wellness modalities, that can be used to improve mental health.

Current guidelines for PPE in the general care of patients with coronavirus disease 2019 (COVID-19) in acute care facilities recommend gloves, an isolation gown, eye protection, and a medical mask or N95 respirator.

COVID-19 increases the risk of blood clotting due to increased activity in blood clotting cells.

Even if they don’t contract the disease, patients living with obesity have found the pandemic to be harmful to their emotional and physical health.

Top news of the week from Pharmacy Times®.

FDA guidance encourages diverse study pools at all phases of development.

A statewide Indiana study shows that 47% of people are using technology to communicate with their health care providers, and less than a quarter are having conversations with their providers about using health information technology (HIT).

Pharmacy students are asked: How has the coronavirus disease 2019 (COVID-19) impacted your education, and how well do you feel prepared for the future?

The findings include airway inflammation and rapid development of pulmonary edema, coronary artery aneurysms, and extensive intra-abdominal inflammatory changes, according to the study authors.

Remdesivir, the investigational drug for the treatment of the coronavirus disease 2019 (COVID-19), will be sold for $390 per vial.

Some states are implementing laws that are allowing pharmacists to expand their roles temporarily, but these laws vary by state and there is no uniformity in what all pharmacists can do during this time.

COVID-19 attacks the cardiovascular system and may exasperate preexisting heart conditions.

Current research has already found that CVD is among the most common pre-existing conditions among people who die from COVID-19.

Pharmacists can play an important role in educating pregnant patients along with individuals planning to become pregnant about COVID-19 prevention strategies and tips to stay healthy during the pandemic.

The crisis affects our economy, education system, and mental and physical health, but pharmacists have a key role to play advocating for patients

Studying blood samples from critically ill patients at the London Health Sciences Center (LHSC), the researchers identified a unique pattern of 6 molecules that could be used as therapeutic targets to treat the virus, as reported in the Critical Care Explorations journal.

The measles, mumps, and rubella vaccine may hold the key to the mystery surrounding children and the COVID-19 pandemic.

Top news of the week from Pharmacy Times®.

Many companies are working with health systems to transition patients from the hospital to in-home care as quickly as possible.

Resulting economic decline Is forces many to make hard choices about medications, but pharmacists can increase awareness and offer solutions.

Pharmacists, being the most accessible health care professionals, have an important role to play in the management of this pandemic.

Managing Oral Oncolytics through COVID-19, a Pharmacy Times Webinar was held live on July 17, 2020.

Although some of the largest insurers have waived their cost sharing requirements, employer-sponsored “self-insured” health insurance plans are not required to adhere to these waivers.

Pharmacists can greatly contribute to herd immunity during this unprecedented health crisis.

Planning on how to address drug and equipment shortages will be essential to continuing patient care in the coming months.

Three student pharmacists share their experiences adapting to APPE rotations during the COVID-19 pandemic,

H2-receptor antagonists, melatonin, and thiamine are some of the adjuvant treatments being evaluated for patients with COVID-19 due to their various immune-enhancing properties and possible antiviral effects.

Pharmacies must take steps to safeguard prescription delivery and verbal communication during the COVID-19 crisis.